DPP4 action in metabolic disease: Role of GLP-1 and other substrates - Dr. Erin Mulvihill, Heart Institute, University of Ottawa

MODR-ErinMulvihill

Schedule

Start 17 December, 2020, 12 PM

End 1 PM

Location

1280 Main St W

Hamilton

ON

Canada

Contact Info

E-Mail: modr@mcmaster.ca

Website


Registration required.

Erin Mulvihill is an Assistant Professor at the University of Ottawa in the Department of Biochemistry, Microbiology and Immunology and is a Scientist at the University of Ottawa Heart Institute. She completed her Ph.D. in Biochemistry at the University of Western
Ontario with Dr. Murray Huff and her post-doctoral training at Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital with Dr. Daniel Drucker. Dr. Mulvihill established her independent research program in July 2017, and a major focus of her lab is to elucidate
how diabetes contributes to an increased risk of cardiovascular disease. Dr. Mulvihill has been awarded the Diabetes Canada New Investigator Award and a CIHR New Investigator award. Her research program is supported by grants from NSERC, CIHR and CFI.

LEARNING OBJECTIVES

  1. To understand the role of dipeptidyl peptidase 4 action on the incretin hormones and its significance in type 2 diabetes
  2. To examine the expanding role of dipeptidyl peptidase in liver and cardiovascular disease



Accessibility for Ontarians With Disabilities Act (AODA)

 

The Faculty of Health Sciences is committed to providing a website that is accessible to the widest possible audience. If there is an accessibility issue with this website, please contact us at fhsweb@mcmaster.ca.